Ono Pharmaceutical (OTCMKTS:OPHLF) Sets New 52-Week High – Should You Buy?
by Danessa Lincoln · The Markets DailyOno Pharmaceutical Co. (OTCMKTS:OPHLF – Get Free Report) shares hit a new 52-week high during trading on Thursday . The company traded as high as $14.00 and last traded at $14.00, with a volume of 200 shares. The stock had previously closed at $12.8696.
Ono Pharmaceutical Stock Performance
The firm has a market capitalization of $6.58 billion, a price-to-earnings ratio of 20.00 and a beta of 0.24. The company has a current ratio of 2.99, a quick ratio of 2.50 and a debt-to-equity ratio of 0.11. The stock has a fifty day moving average price of $12.69 and a 200-day moving average price of $11.61.
Ono Pharmaceutical (OTCMKTS:OPHLF – Get Free Report) last issued its quarterly earnings data on Thursday, October 30th. The company reported $0.32 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.27 by $0.05. Ono Pharmaceutical had a return on equity of 6.13% and a net margin of 9.75%.The firm had revenue of $876.10 million during the quarter, compared to the consensus estimate of $790.87 million.
Ono Pharmaceutical Company Profile
Ono Pharmaceutical Co, Ltd., founded in 1717 and headquartered in Osaka, Japan, is a research‐based pharmaceutical company specializing in the discovery, development and marketing of innovative therapies. With origins as a traditional pharmacy, Ono has grown into a global biopharmaceutical entity focused on delivering new treatment options across several therapeutic areas, including oncology, immunology, cardiovascular and antiviral diseases. The company conducts comprehensive research programs spanning early drug discovery through to clinical development.
One of Ono’s most recognized products is the immune checkpoint inhibitor nivolumab, marketed in collaboration with Bristol-Myers Squibb under the trade name Opdivo.